siRNA

Title: RNA Interference Modulators of Hedgehog Signaling and Uses Thereof
Patent Number: 8,802,639
Filed: March 24, 2005

NEW YORK (GenomeWeb) – InteRNA Technologies and academic collaborators this month reported details of an siRNA-delivery technology capable of specifically targeting tumor vasculature, along with in vitro data demonstrating its ability to carry siRNAs into human umbilical vein endothelial

Should Dicerna Pharmaceuticals complete its planned initial public offering, the company would be the first RNAi drug developer to go public since Alnylam Pharmaceuticals did so in 2004.

This article has been updated to include information about Life Technologies' spokesperson.

Looking to harness the gene-silencing efficiency of siRNAs to enhance the potency of disease-targeting microRNAs, a team of researchers from Washington University has developed new molecules that incorporate features of both classes of small RNAs.

Theradiag has named four members of its newly formed scientific advisory board who will help the company develop a microRNA-based diagnostic for characterizing HIV tropism.

Merck this week announced a broad restructuring that will include the elimination of roughly 8,500 jobs and a reduction in the company's annual operating expenses by $2.5 billion by the end of 2015.

Life Technologies announced this week that it has signed a licensing agreement giving Suzhou Ribo Life Sciences the exclusive rights to use its Invivofectamine Rx delivery technology in the development and manufacturing of siRNA therapeutics in China.